Monday, 24 Feb 2020

You are here

Smoking Cessation Lowers RA Disease Activity and CV Risks

A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.

Smoking is not only a known risk factor for the development of both cardiovascular disease (CVD) and RA, it has also been repeatedly shown to blunt treatment (biologics and DMARD) responses in RA patients.

RA patients, without prior CVD, from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico) were studied. The cohort included 3311 RA patients (1012 former, 887 current and 1412 never smokers).

WIth a median follow-up of 3.5 years, 235 experienced a CV event. At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P < 0.001 for both).

Overall, former and never smokers had significantly lower CVD event rates compared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P = 0.02 and 0.48 (0.34, 0.69), P < 0.001, respectively].

The CVD event rates for former and never smokers were comparable.

Smoking cessation in patients with RA was associated with lower disease activity and improved lipid profiles and was a predictor of reduced rates of CVD events.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Seronegativity on the Rise in RA

Although the overall incidence rates of rheumatoid arthritis (RA) have remained stable over recent decades, there has been a significant increase in seronegative cases, a retrospective study showed.

Alcohols Net Zero Effect in Rheumatoid Arthritis

A report from The National Databank for Rheumatic Disease addressed the impact of alcohol on disease activity and mortality in rheumatoid arthritis (RA) and found that alcohol use was not associated with changes in disease activity or mortality, after addressing confounders. 

DMARD Inertia by Registry Rheumatologists

A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).

Bariatric Weight Loss Fails to Alter RA Risk

Obesity has been shown to be a risk factor for the onset of rheumatoid arthritis (RA) and also shown to affect outcomes by impairing responses to many DMARD therapies. A Swiss study of RA patients undergoing bariatric surgery failed to show that bariatric surgery and weight loss had any effect on the incidence of RA.

Limited Advantage to Very Early vs. Delayed Etanercept in RA

The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.